Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-CD123/CD3-monoclonal-antibody-MGD006, CD123 x CD3(MacroGenics/Servier), CD123xCD3-DART-bispecific-antibody-MGD006 + [8] |
Target |
Mechanism CD123 inhibitors(Interleukin-3 receptor subunit alpha inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Biphenotypic Leukemia | Phase 2 | - | 20 Oct 2020 | |
acute leukemia | Phase 2 | - | 20 Oct 2020 | |
Acute lymphoblastic leukemia recurrent | Phase 2 | - | 20 Oct 2020 | |
Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | - | 20 Oct 2020 | |
CD123 Positive Hematologic Neoplasms | Phase 2 | - | 20 Oct 2020 | |
Hairy Cell Leukemia | Phase 2 | - | 20 Oct 2020 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 2 | - | 20 Oct 2020 | |
Recurrent Hematologic Malignancy | Phase 2 | - | 20 Oct 2020 | |
Recurrent Hodgkin Lymphoma | Phase 2 | - | 20 Oct 2020 | |
Refractory Adult Acute Lymphoblastic Leukemia | Phase 2 | - | 20 Oct 2020 |
Phase 1/2 | 88 | qcabggxdyx(olqfboqtdd) = egoqxvshdg uxrjquvvbg (qehhnlnibn ) View more | Positive | 11 Feb 2021 | |||
Not Applicable | - | gnvtetfors(lzcbkzusfd) = avkaldrgsn hxswfwcmsg (vjbkkfudxy ) View more | - | 14 Jun 2019 | |||
gnvtetfors(lzcbkzusfd) = hfpedlcfyo hxswfwcmsg (vjbkkfudxy ) View more |